| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1009736506 |
| P356 | DOI | 10.1186/BCR2607 |
| P8608 | Fatcat ID | release_tqap3ckrdjffzghkz2gudhmfcy |
| P932 | PMC publication ID | 2949637 |
| P698 | PubMed publication ID | 20804570 |
| P5875 | ResearchGate publication ID | 46094585 |
| P50 | author | Jorge Reis-Filho | Q23892845 |
| Stephen Fox | Q30506440 | ||
| Jocelyne Jacquemier | Q42215390 | ||
| Sunil Badve | Q47145679 | ||
| Emad A. Rakha | Q55098175 | ||
| Sunil R. Lakhani | Q55136888 | ||
| Ian Ellis | Q55300055 | ||
| Fernando Schmitt | Q37382197 | ||
| David J Dabbs | Q89153719 | ||
| Frederick L Baehner | Q91858189 | ||
| Andrea S Richardson | Q92038767 | ||
| Stuart J Schnitt | Q114292959 | ||
| P2093 | author name string | Thomas Decker | |
| José Palacios | |||
| Vincenzo Eusebi | |||
| Puay-Hoon Tan | |||
| Shu Ichihara | |||
| Gary M Tse | |||
| P2860 | cites work | Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 |
| A gene-expression signature as a predictor of survival in breast cancer | Q27860945 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 | ||
| Genomic and transcriptional aberrations linked to breast cancer pathophysiologies | Q29619120 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma | Q30465451 | ||
| The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade | Q37635788 | ||
| Challenges in projecting clustering results across gene expression-profiling datasets | Q38296482 | ||
| Revision of the American Joint Committee on Cancer staging system for breast cancer | Q38432706 | ||
| High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses | Q38443265 | ||
| Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis | Q39747830 | ||
| Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? | Q40248150 | ||
| The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). | Q41054346 | ||
| Histological grading of breast carcinomas: a study of interobserver agreement. | Q41679144 | ||
| ONCOPOOL - a European database for 16,944 cases of breast cancer. | Q43265459 | ||
| The assessment of histological differentiation in breast cancer. | Q43770441 | ||
| Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes | Q43802690 | ||
| Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index | Q44118465 | ||
| Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? | Q44606345 | ||
| Observer variation in histological grading of breast cancer | Q45003669 | ||
| Tubular carcinoma of the breast: further evidence to support its excellent prognosis | Q45146452 | ||
| A molecular signature of the Nottingham prognostic index in breast cancer | Q47652272 | ||
| Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast | Q50661847 | ||
| Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype | Q50665044 | ||
| Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. | Q51796674 | ||
| Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. | Q52069703 | ||
| [Reproducibility of histoprognostic grades of invasive breast cancer] | Q52907348 | ||
| Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. | Q52920767 | ||
| Interobserver agreement of the Nottingham histologic grading scheme for infiltrating duct carcinoma breast. | Q52924277 | ||
| Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. | Q53364525 | ||
| Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. | Q53461482 | ||
| Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes | Q57660183 | ||
| Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma | Q64018963 | ||
| Reading the prognosis of the individual with breast cancer | Q64018968 | ||
| The prognosis of small primary breast cancers | Q64019046 | ||
| The Nottingham prognostic index in primary breast cancer | Q64019104 | ||
| Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). | Q32092475 | ||
| Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival | Q33831109 | ||
| Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. | Q33963908 | ||
| Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients | Q33970353 | ||
| Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. | Q33987206 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Preoperative assessment of prognostic factors in breast cancer | Q34197110 | ||
| Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years | Q34468189 | ||
| "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers | Q34549766 | ||
| Concordance among gene-expression-based predictors for breast cancer | Q34555829 | ||
| Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. | Q35006280 | ||
| Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma | Q35585987 | ||
| Impact of a national external quality assessment scheme for breast pathology in the UK | Q35769734 | ||
| Breast cancer classification and prognosis based on gene expression profiles from a population-based study | Q35918291 | ||
| An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens | Q36172499 | ||
| Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study | Q36338011 | ||
| Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature | Q36464108 | ||
| Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. | Q36588459 | ||
| Pathology characteristics that optimize outcome prediction of a breast screening trial | Q36642193 | ||
| Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics | Q36916152 | ||
| Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures | Q36955113 | ||
| Molecular subtypes in breast cancer evaluation and management: divide and conquer | Q37052739 | ||
| Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? | Q37356684 | ||
| Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). | Q37361977 | ||
| Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance | Q68078160 | ||
| Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas | Q69356806 | ||
| Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer | Q71127399 | ||
| The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years | Q73459311 | ||
| Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189 | Q73794145 | ||
| Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group | Q77333227 | ||
| Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy | Q77764385 | ||
| Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor | Q77948285 | ||
| Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study | Q79821845 | ||
| Interobserver variation in breast cancer grading: a statistical modeling approach | Q80156414 | ||
| Predicting features of breast cancer with gene expression patterns | Q80765754 | ||
| P433 | issue | 4 | |
| P921 | main subject | breast cancer | Q128581 |
| gene expression profiling | Q1502169 | ||
| breast neoplasm | Q23929670 | ||
| neoplastic gene expression regulation | Q66660300 | ||
| P304 | page(s) | 207 | |
| P577 | publication date | 2010-07-30 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Breast cancer prognostic classification in the molecular era: the role of histological grade | |
| P478 | volume | 12 |
| Q90461821 | A Review on Mammary Tumors in Rabbits: Translation of Pathology into Medical Care |
| Q30587056 | A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer |
| Q64256232 | A data-driven interactome of synergistic genes improves network-based cancer outcome prediction |
| Q34334455 | A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling |
| Q92199204 | A key genomic subtype associated with lymphovascular invasion in invasive breast cancer |
| Q36990777 | A microscopic landscape of the invasive breast cancer genome |
| Q54333856 | A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. |
| Q36664694 | A new genome-driven integrated classification of breast cancer and its implications |
| Q91605601 | A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients |
| Q35610804 | A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer |
| Q36827898 | Additional Value of Diffusion-Weighted Imaging to Evaluate Prognostic Factors of Breast Cancer: Correlation with the Apparent Diffusion Coefficient |
| Q33892460 | An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer |
| Q99365555 | Analysis of single-cell transcriptomes links enrichment of olfactory receptors with cancer cell differentiation status and prognosis |
| Q36574461 | Application of imaging mass spectrometry for the molecular diagnosis of human breast tumors. |
| Q38105487 | Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer? |
| Q39263199 | Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany |
| Q38758934 | Assessment of Functional Differences in Malignant and Benign Breast Lesions and Improvement of Diagnostic Accuracy by Using US-guided Diffuse Optical Tomography in Conjunction with Conventional US. |
| Q84806666 | Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy |
| Q64949421 | Attention-Based Multi-NMF Deep Neural Network with Multimodality Data for Breast Cancer Prognosis Model. |
| Q64234502 | Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support |
| Q48353102 | Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology |
| Q92916959 | Breast Cancer Heterogeneity in Primary and Metastatic Disease |
| Q64080831 | Breast Cancer Prognostic Factors in the Digital Era: Comparison of Nottingham Grade using Whole Slide Images and Glass Slides |
| Q92982939 | Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option? |
| Q58604437 | Breast Cancer in Basra Oncology Center: A Clinico- Epidemiological Analysis |
| Q39436785 | Breast cancer by age at diagnosis in the Gharbiah, Egypt, population-based registry compared to the United States Surveillance, Epidemiology, and End Results Program, 2004-2008. |
| Q30245184 | Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications |
| Q42473382 | Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights |
| Q37107535 | Breast cancer survival disparity between African American and Caucasian women in Arkansas: A race-by-grade analysis |
| Q99557519 | Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status |
| Q47144882 | CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis |
| Q50893707 | Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization. |
| Q52648398 | CircRNAs as biomarkers of cancer: a meta-analysis. |
| Q39986271 | Circulating Tumor Cells and Tumor Stem Cells Detection in the Peripheral Blood Mononuclear Cells of Breast Cancer. |
| Q37082568 | Classical pathology and mutational load of breast cancer - integration of two worlds |
| Q90091240 | Classification models for Invasive Ductal Carcinoma Progression, based on gene expression data-trained supervised machine learning |
| Q34042565 | Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression. |
| Q99609740 | Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer |
| Q57517727 | Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative |
| Q37218900 | Clinical and Biological Significance of Cathepsin D Levels in Breast Cancer Cytosol in Women Over 70 years |
| Q47196323 | Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients |
| Q84705036 | Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer |
| Q89455737 | Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients |
| Q33988310 | Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer |
| Q44089144 | Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal |
| Q88774238 | Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay |
| Q47163676 | Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers |
| Q47690008 | Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast |
| Q50929945 | Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas |
| Q33921791 | Computational prognostic indicators for breast cancer. |
| Q30416061 | Computer-aided assessment of tumor grade for breast cancer in ultrasound images |
| Q64085551 | Concomitant Expression of Prolactin Receptor and TGFβ Receptors in Breast Cancer: Association with Less Aggressive Phenotype and Favorable Patient Outcome |
| Q89219479 | Correlation Between Contrast-enhanced Ultrasound Characteristics (Qualitative and Quantitative) and Pathological Prognostic Factors in Breast Cancer |
| Q55404783 | Correlation between minimum apparent diffusion coefficient values and the histological grade of breast invasive ductal carcinoma. |
| Q44876420 | Cytogenomics of Feline Cancers: Advances and Opportunities. |
| Q37686041 | DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms |
| Q36013671 | Determining breast cancer histological grade from RNA-sequencing data |
| Q34514418 | Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a |
| Q93093879 | Differential Expression of TFF Genes and Proteins in Breast Tumors |
| Q35765833 | Differential immune cell densities in ductal carcinoma In-Situ and invasive breast cancer: Possible role of leukocytes in early stages of carcinogenesis |
| Q90643299 | Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients |
| Q51061326 | Diffusion magnetic resonance imaging in breast cancer characterisation: correlations between the apparent diffusion coefficient and major prognostic factors |
| Q37432458 | Disease-on-a-chip: mimicry of tumor growth in mammary ducts |
| Q49387003 | Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: Clinicopathological associations and prognostic relevance |
| Q33994291 | Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis |
| Q36903234 | Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers |
| Q90333840 | Enhancing Breast Cancer Treatment Using a Combination of Cannabidiol and Gold Nanoparticles for Photodynamic Therapy |
| Q35503492 | Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value |
| Q58774667 | Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis |
| Q55365778 | Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients. |
| Q33723841 | Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells |
| Q91596489 | Expression profile of Toll‑like receptors in human breast cancer |
| Q37693530 | Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. |
| Q33761830 | GD2 expression in breast cancer. |
| Q90577383 | GSIAR: gene-subcategory interaction-based improved deep representation learning for breast cancer subcategorical analysis using gene expression, applicable for precision medicine |
| Q64067192 | GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner |
| Q36558848 | Gene expression analysis supports tumor threshold over 2.0 cm for T-category breast cancer |
| Q34559124 | Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study |
| Q36546754 | Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development |
| Q26865893 | Genomic approaches in breast cancer research |
| Q90445914 | Glycosylated Hemoglobin A1c Is Associated with Anthropometric Measurements and Tumor Characteristics in Breast Cancer Patients |
| Q92240800 | Grade-specific diagnostic and prognostic biomarkers in breast cancer |
| Q53185082 | Histamine H4 receptor signalling in tongue cancer and its potential role in oral carcinogenesis - a short report. |
| Q57787389 | Histological Grade: Analysis of Prognosis of Non-small Cell Lung Cancer After Complete Resection |
| Q92155276 | Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study |
| Q33555247 | Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma |
| Q39267625 | Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. |
| Q41769537 | Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets |
| Q61814080 | Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer |
| Q90447942 | Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3 |
| Q36463610 | Identifying grade/stage-related active modules in human co-regulatory networks: a case study for breast cancer |
| Q35807180 | Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. |
| Q34198351 | Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data |
| Q64055694 | Impact of Obesity on Clinicopathologic Characteristics and Disease Prognosis in Pre- and Postmenopausal Breast Cancer Patients: A Retrospective Institutional Study |
| Q31052319 | Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example |
| Q38804973 | Improving your four-dimensional image: traveling through a decade of light-sheet-based fluorescence microscopy research |
| Q45134639 | Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System |
| Q99609982 | Incorporation of biologic factors for the staging of de novo stage IV breast cancer |
| Q90700166 | Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice |
| Q35370090 | Insight into the heterogeneity of breast cancer through next-generation sequencing |
| Q37968654 | Integrating breast cancer genetics into clinical practice. |
| Q33670486 | Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition |
| Q40155925 | Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes |
| Q57159647 | Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence |
| Q37355949 | Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature |
| Q47335043 | Invasive ductal carcinoma: relationship between pathological characteristics and the presence of axillary metastasis in 220 cases |
| Q55396783 | Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. |
| Q35086250 | Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes |
| Q37947916 | Is gene array testing to be considered routine now? |
| Q36862615 | LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer |
| Q55023953 | Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer. |
| Q21195193 | Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes |
| Q54344267 | Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis. |
| Q37302614 | MUCI positive cutaneous metastasis with transepidermal elimination from a breast carcinoma |
| Q38761797 | Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors |
| Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q37191427 | Metabolic syndrome and pre-diabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways |
| Q83547346 | Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype |
| Q37190321 | MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer |
| Q34820314 | Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement |
| Q35558070 | Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction |
| Q37130372 | Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations |
| Q38933747 | Mining cancer gene expression databases for latent information on intronic microRNAs |
| Q42686538 | Model predictions for the wide-angle x-ray scatter signals of healthy and malignant breast duct biopsies |
| Q42135091 | Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. |
| Q42510389 | Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women |
| Q38216166 | Molecular classification of breast cancer |
| Q39410000 | Molecular signatures in breast cancer. |
| Q39614413 | Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. |
| Q37094017 | Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients |
| Q37383276 | Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. |
| Q89924122 | Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer |
| Q28646873 | New breast cancer prognostic factors identified by computer-aided image analysis of HE stained histopathology images |
| Q41702637 | New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes |
| Q88718087 | No association of reproductive risk factors with breast cancer tumor grade |
| Q37681710 | Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. |
| Q35609695 | Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. |
| Q41120614 | Nuclear grade plus proliferation grading system for invasive ductal carcinoma of the breast: validation in a tertiary referral hospital cohort |
| Q39207451 | Nuclear pleomorphism: role in grading and prognosis of canine mammary carcinomas |
| Q88630599 | Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis |
| Q38637991 | Overexpression of cofilin correlates with poor survival in breast cancer: A tissue microarray analysis. |
| Q58584856 | PWCDA: Path Weighted Method for Predicting circRNA-Disease Associations |
| Q39789244 | Pattern of relapse after breast conserving therapy, a study of 1519 early breast cancer patients treated in the Central Region of Denmark 2000-2009. |
| Q34206647 | Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. |
| Q47557745 | Phase distribution analysis of tissues based on the off-axis digital holographic hybrid reconstruction algorithm |
| Q28067626 | Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine |
| Q41661268 | Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer |
| Q36989546 | Practical implications of gene-expression-based assays for breast oncologists. |
| Q35125648 | Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q38205199 | Prognostic evaluation of feline mammary carcinomas: a review of the literature. |
| Q41049866 | Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA. |
| Q36231009 | Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. |
| Q44477076 | Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis |
| Q46540170 | Proposed classification of the feline "complex" mammary tumors as ductal and intraductal papillary mammary tumors |
| Q98188008 | Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosis |
| Q34190743 | Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. |
| Q40983403 | Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer |
| Q37622317 | Racial disparities in survival and age-related outcome in postsurgery breast cancer patients in a new york city community hospital. |
| Q36989560 | Rapid staining and imaging of subnuclear features to differentiate between malignant and benign breast tissues at a point-of-care setting |
| Q35608690 | Rare variants in the ATM gene and risk of breast cancer |
| Q37407119 | Recent perspectives of breast cancer prognosis and predictive factors |
| Q28730529 | Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma |
| Q89637117 | SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells |
| Q37388652 | Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast |
| Q38599786 | Separase is a marker for prognosis and mitotic activity in breast cancer. |
| Q92155385 | Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives |
| Q36241514 | Serum Oxidative Stress Markers and Genotoxic Profile Induced by Chemotherapy in Patients with Breast Cancer: A Pilot Study |
| Q93048654 | Significant inter- and intra-laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands |
| Q28078729 | Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice |
| Q34647811 | Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. |
| Q91920011 | Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting |
| Q38104568 | Taxane benefit in breast cancer--a role for grade and chromosomal stability |
| Q95725437 | The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman |
| Q92730933 | The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer |
| Q90677046 | The Immune Landscape in Women Cancers |
| Q30446768 | The biology of malignant breast tumors has an impact on the presentation in ultrasound: an analysis of 315 cases |
| Q38132239 | The classification of invasive carcinoma of the breast |
| Q38827388 | The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients |
| Q94671576 | The effect of an e-learning module on grading variation of (pre)malignant breast lesions |
| Q37691054 | The genomic map of breast cancer: which roads lead to better targeted therapies? |
| Q39144949 | The method for breast cancer grade prediction and pathway analysis based on improved multiple kernel learning |
| Q39175548 | The molecular basis of breast cancer pathological phenotypes |
| Q34752938 | The molecular pathology of breast cancer progression |
| Q35037251 | The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression |
| Q34277400 | The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data |
| Q64018926 | The prognostic significance of lymphovascular invasion in invasive breast carcinoma |
| Q35867697 | The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer |
| Q47289284 | The reliability of histological grade in breast cancer core needle biopsies depends on biopsy size: a comparative study with subsequent surgical excisions |
| Q48103743 | The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis |
| Q36734385 | Therapeutic targeting of casein kinase 1δ in breast cancer |
| Q37652666 | Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. |
| Q47146956 | Tumor Heterogeneity in Breast Cancer |
| Q36411711 | Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population |
| Q60921036 | Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas |
| Q57192072 | Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China |
| Q39666322 | Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy |
| Q39022194 | Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients. |
| Q28258209 | Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer |
| Q93012581 | Visceral fat metabolic activity evaluated by preoperative 18F-FDG PET/CT significantly affects axillary lymph node metastasis in postmenopausal luminal breast cancer |
| Q57498203 | p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy |
Search more.